Brief: Homology Medicines Presents Details Of Optimized HMI-103 Nuclease-Free Gene Editing Candidate
18/05/2022 11:16
May 18 (Reuters) - Homology Medicines Inc FIXX.O :
* HOMOLOGY MEDICINES PRESENTS DETAILS OF OPTIMIZED HMI-103 NUCLEASE-FREE
GENE
EDITING CANDIDATE FEATURING INTEGRATED LIVER-SPECIFIC PROMOTER TO MAXIMIZE
LONG-TERM EXPRESSION
Source text for Eikon: ID:nGNX1rVTcK
Further company coverage: FIXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview